Amiodarone (AM) is an antiarrhythmic agent widely used in the treatment of ventricular and supraventricular arrhythmias. Dronedarone (DR) is a new compound with a pharmacological profile similar to that of AM, but iodine free. We previously demonstrated that chronic AM treatment reduces transmural dispersion of repolarization (TDR) in the canine heart. We used standard microelectrode technique to evaluate the effects of acute AM (100 µM) and DR (30 µM) on epicardial (EPI), endocardial (ENDO), and M region tissues obtained from the left ventricular wall of the canine heart. Amiodarone (100 µM, 120 min of exposure) produced little change in the action potential duration of ENDO and EPI tissues, but it shortened the action potential of M cells, especially at slow rates, leading to a decrease in TDR. Similar results were observed with DR. Acute AM (100 µM) and DR (30 µM) eliminated d-sotalol—induced early afterdepolarizations (EADs) and triggered activity in 3 of 3 and 2 of 6 M cell preparations, respectively. The reduction of TDR and the elimination of EAD-induced triggered activity differentiates AM and DR from other class III agents. These effects may explain the efficacy and low arrhythmogenicity of acute AM and suggest a potential safe use of DR as an antiarrhythmic agent.
Rosenbaum MB , Chiale PA, Halpern MS, et al. Clinical efficacy of amiodarone as an antiarrhythmic agent. Am J Cardiol.1976 ;38:934-944.
2.
Weinberg BA, Miles WM, Klein LS, et al. Five-year follow-up of 589 patients treated with amiodarone . Am Heart J.1993;125:109-120.
3.
Singh BN, Vaughan-Williams EMThe effect of amiodarone, a new anti-anginal drug, on cardiac muscle. Br J Pharmacol.1970;39:657-667.
4.
Varro A., Nakaya Y., Elharrar V., Surawicz B.Use-dependent effects of amiodarone on Vmax in cardiac Purkinje and ventricular muscle fibers. Eur J Pharmcol. 1985;112: 419-422.
5.
Kadish AH, Chen R-F., Schmaltz S., Morady F.Magnitude and time course of beta-adrenergic antagonism during oral amiodarone therapy. J Am Coll Cardiol.1990;16: 1240-1245.
6.
Nattel S., Talajic M., Quantz MA, De RoodeMRFrequency-dependent effects of amiodarone on atrioventricular nodal function and slow-channel action potentials: evidence for calcium channel blocking activities. Circulation. 1987;76:442-449.
7.
Patterson E. , Eller BT, Abrams GD, Vasiliades J., Lucchesi BRVentricular fibrillation in a conscious canine preparation of sudden coronary death—prevention by short- and long-term amiodarone administration. Circulation. 1983 ;68:857-864.
8.
Gallagher JD , Bianchi J., Gessman LJA comparison of the electrophysiological effects of acute and chronic amiodarone administration on canine Purkinje fibers. J Cardiovasc Pharmacol.1989;13:723-729.
9.
Yabek SM, Kato R., Singh BNAcute effects of amiodarone on the electrophysiologic properties of isolated neonatal and adult cardiac fibers. J Am Coll Cardiol.1985;5:1109-1115.
10.
Hohnloser SH , Klingenheben T., Singh BNAmiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia. Ann Intern Med.1994;121:529-535.
11.
Sicouri S., Moro S., Litovsky SH, Elizari MV, Antzelevitch C.Chronic amiodarone reduces transmural dispersion of repolarization in the canine heart. J Cardiovasc Electrophysiol. 1997;8:1269-1279.
12.
Martin W., Rosenow E.Amiodarone pulmonary toxicity recognition and pathogenesis. Chest. 1988;93:1067-1075.
13.
Chatelain P., Meysmans L., Matteazzi JR, Beaufort P., Clinet M.Interaction of the antiarrhythmic agents SR 33589 and amiodarone with the beta-adrenoceptor and adenylate cyclase in rat heart. Br J Pharmacol.1995; 116:1949-1956.
14.
Finance O., Manning A., Chatelain P.Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, D,L-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs. J Cardiovasc Pharmacol.1995;26:570-576.
15.
Manning AS, Bruyninckx C., Ramboux J., Chatelain P.SR 33589, a new amiodarone-like agent: effect on ischemia-and reperfusion-induced arrhythmias in anesthetized rats. J Cardiovasc Pharmacol.1995;26:453-461.
16.
Hodeige D., Heyndrickx JP, Chatelain P., Manning A.SR 33589, a new amiodarone-like antiarrhythmic agent: anti-adrenoceptor activity in anesthetized and conscious dogs. Eur J Pharmacol.1995;279:25-32.
17.
Manning A., Thisse V., Hodeige D., Richard J., Heyndrickx JP, Chatelain P.SR 33589, a new amiodarone-like antiarrhythmic agent: electrophysiological effects in anesthetized dogs. J Cardiovasc Pharmacol.1995;25:252-261.
18.
Stark G., Stark U., Windisch H., et al. Comparison of acute electrophysiological effects of amiodarone and its metabolite desethylamiodarone in Langendorff perfused guinea pig hearts . Basic Res Cardiol. 1991;86:136-147.
19.
Morady F., Dicarlo LA, Krol RB, Baerman JM, De Buitleir M.Acute and chronic effects of amiodarone on ventricular refractoriness, intraventricular conduction and ventricular tachycardia induction. J Am Coll Cardiol.1986;7:148-157.
20.
Singh BNAmiodarone: historical development and pharmacologic profile. Am Heart J.1983;106:788-797.
21.
Eddlestone GT, Zygmunt AC, Antzelevitch C.Larger late sodium conductance in M cells contributes to electrical heterogeneity in canine ventricle. Am J Physiol Heart Circ Physiol. 2001;281:H689-697.
22.
Papp JG, Nemeth M., Krassoi I., Mester L., Hala O., Varro A.Differential electrophysiologic effects of chronically administered amiodarone on canine Purkinje fibers versus ventricular muscle. J Cardiovasc Pharmacol Ther.1996;4:287-296.
23.
Kamiya K., Nishiyama A., Yasui K., Hojo M., Sanguinetti MC, Kodama I.Short- and long-term effects of amiodarone on the two components of cardiac delayed rectifier K(+) current. Circulation.2001;103:1317-1324.
24.
Antzelevitch C., Sicouri S.Clinical relevance of cardiac arrhythmias generated by afterdepolarizations: the role of M cells in the generation of U waves, triggered activity and torsade de pointes. J Am Coll Cardiol.1994;23:259-277.
25.
Sicouri S., Moro S., Elizari MVd-Sotalol induces marked action potential prolongation and early afterdepolarizations in M but not epicardial or endocardial cells of the canine ventricle. J Cardiovasc Pharmacol Ther.1997;2:27-38.
26.
Varro A., Takacs J., Nemeth M., et al. Electrophysiological effects of dronedarone (SR 33589), a noniodinated amiodarone derivative in the canine heart: comparison with amiodarone. Br J Pharmacol.2001;133:625-634.
27.
Verduyn SC, Vos MA, Leunissen HD, van Opstal JM, Wellens HJEvaluation of the acute electrophysiological effects of intravenous dronedarone, an amiodarone-like agent, with special emphasis on ventricular repolarization and acquired torsade de pointes arrhythmias. J Cardiovasc Pharmacol.1999;33;212-222.
28.
van Opstal JM, Schoenmakers M., Verduyn SC, et al. Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome. Circulation. 2001;104: 2722-2727.
29.
Lalevee N., Nargeot J., Barrere-Lemaire S., Gautier P., Richard S.Effects of amiodarone and dronedarone on voltage-dependent sodium current in human cardiomyocytes. J Cardiovasc Electrophysiol. 2003;14:885-890.
30.
Drouin E., Charpentier F., Gauthier C., Laurent K., Le Marec H.Electrophysiological characteristics of cells spanning the left ventricular wall of the human heart: evidence for the presence of M cells. J Am Coll Cardiol.1995;26:185-192.
31.
Sicouri S., Antzelevitch C.A subpopulation of cells with unique electrophysiological properties in the deep subepicardium of the canine ventricle: the M cell. Circ Res.1991;68:1729-1741.
32.
Liu DW, Antzelevitch C.Characteristics of the delayed rectifier current (IKr and I Ks) in canine ventricular epicardial, midmyocardial and endocardial myocytes: a weaker IKs contributes to the longer action potential of the M cell. Circ Res.1995;76:351-365.
33.
Thomas D., Kathofer S., Zhang W., et al. Acute effects of dronedarone on both components of the cardiac delayed rectifier K+ current, HERG and KvLQT1/minK potassium channels. Br J Pharmacol.2003;140:996-1002. Epub September 29, 2003.
34.
Gautier P., Marion A., Bertrand JP, Tourneur Y., Nisato D.Electrophysiological characterization of dronedarone (SR33589), a new amiodarone-like agent, in cardiac ventricular myocytes. J Cardiovasc Pharmacol.2003; 41:191-202.
35.
Touboul P., Brugada J., Capucci A., et al. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J.2003;24:1481-1487.
36.
Celestino D. , Medei E., Moro S., Elizari MV, Sicouri S.Acute in vitro effects of dronedarone, an iodine-free derivative and amiodarone, on the rabbit sinoatrial node automaticity. A comparative study. J Cardiovasc Pharmacol Ther. In press.
